<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01585857</url>
  </required_header>
  <id_info>
    <org_study_id>8606</org_study_id>
    <nct_id>NCT01585857</nct_id>
  </id_info>
  <brief_title>ADIPOA - Clinical Study</brief_title>
  <official_title>A Phase I, Prospective, Bi-centric,Single -Arm, Open-label, Dose-escalating Clinical Trial to Evaluate the Safety of a Single Injection of Autologous Adipose Derived Mesenchymal Stromal Cells in the Treatment of Severe Osteoarthritis of the Knee Joint</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary:

      To study the safety of a single injection of autologous adipose derived mesenchymal stromal
      cells (ASCs) on patients with moderate or severe osteoarthritis of the knee (OA).

      Secondary:

      To study the efficacy of a single injection of autologous adipose derived mesenchymal stromal
      cells on patients with moderate or severe osteoarthritis of the knee (OA).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recording of Serious Adverse Events</measure>
    <time_frame>during 365 days following injection</time_frame>
    <description>Adverse events will be described with respect to seriousness, intensity, relationship to treatment, action taken and outcome of the adverse event.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional status of the knee</measure>
    <time_frame>during 365 days following injection</time_frame>
    <description>Efficacy will be assessed by measuring:
WOMAC (Western Ontario and McMaster Universities osteoarthritis index),
Short Arthritis assessment Scale (SAS),
range of motion of the target knee joint,
imaging through MRI evaluation, dGEMRIC and T1rho MRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>during 365 days following injection</time_frame>
    <description>Quality of life will be assessed by measuring:
pain-specific assessment
global patient assessment (visual analog scale, Short-Form 8)
decrease in rescue paracetamol medication.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 x 10E6 ASC intra-articular injection (5 ml)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 x 10E6 ASC intra-articular injection (5 ml)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 x 10E6 ASC intra-articular injection (5 ml)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous adipose derived stem cells administrated for intra-articular use</intervention_name>
    <description>Each patient will receive one single administration of the cells and will be followed for 3 months. Each patients will be follow-up during one year with routinely examinations for safety issues.</description>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous adipose derived stem cells administrated for intra-articular use</intervention_name>
    <description>Each patient will receive one single administration of the cells and will be followed for 3 months. Each patients will be follow-up during one year with routinely examinations for safety issues. The first patient will be followed during 12 weeks before inclusion of the second patient.</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  OA diagnosis should fulfil the criteria of the American College of Rheumatology (ACR)
             with moderate or severe medial and/ or external femorotibial knee osteoarthritis (OA)
             (stage 3 or 4) and indication total knee arthroplasty.

        Exclusion Criteria:

          -  Any disease or medication affecting the bone or cartilage metabolism, including
             corticoids.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Jorgensen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UH Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orthopädische Klinik</name>
      <address>
        <city>Würzburg</city>
        <zip>97074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2012</study_first_submitted>
  <study_first_submitted_qc>April 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2012</study_first_posted>
  <last_update_submitted>December 3, 2014</last_update_submitted>
  <last_update_submitted_qc>December 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

